Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis Slamon

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Cancer Cell|June 28, 2002
Smart drugs: tyrosine kinase inhibitors in cancer therapyLaura K Shawver, Dennis Slamon, Axel Ullrich
Cancer Research|June 17, 2010
FOXO1A is a target for HER2-overexpressing breast tumorsYanyuan Wu, Xiying Shang, Marianna Sarkissyan, et al.
Breast Cancer Research : BCR|January 11, 2008
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancerYanyuan Wu, Hezla Mohamed, Ram Chillar, et al.
Gynecologic Oncology|December 13, 2002
A human ovarian carcinoma murine xenograft model useful for preclinical trialsJohn C Elkas, Rae Lynn Baldwin, Mark Pegram, et al.
Molecular Cancer Research : MCR|October 17, 2012
Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cellsYanyuan Wu, Charles Ginther, Juri Kim, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2007
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCarolyn D Britten, Fairooz Kabbinavar, J Randolph Hecht, et al.
Cancer Research|December 20, 2007
RIN1 is a breast tumor suppressor geneMarc Milstein, Chelsea K Mooser, Hailiang Hu, et al.
Nature Reviews. Cancer|March 27, 2007
Shaping the future of biomarker research in breast cancer to ensure clinical relevanceM Carolina Hinestrosa, Kay Dickersin, Pamela Klein, et al.
Breast Cancer Research and Treatment|January 4, 2013
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancerStephen R D Johnston, Henry Gómez, Salomon M Stemmer, et al.
Breast Cancer Research : BCR|July 1, 2005
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapiesFrancisco J Esteva, Carol D Cheli, Herbert Fritsche, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Cancer Cell|June 28, 2002
Smart drugs: tyrosine kinase inhibitors in cancer therapyLaura K Shawver, Dennis Slamon, Axel Ullrich
Cancer Research|June 17, 2010
FOXO1A is a target for HER2-overexpressing breast tumorsYanyuan Wu, Xiying Shang, Marianna Sarkissyan, et al.
Breast Cancer Research : BCR|January 11, 2008
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancerYanyuan Wu, Hezla Mohamed, Ram Chillar, et al.
Gynecologic Oncology|December 13, 2002
A human ovarian carcinoma murine xenograft model useful for preclinical trialsJohn C Elkas, Rae Lynn Baldwin, Mark Pegram, et al.
Molecular Cancer Research : MCR|October 17, 2012
Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cellsYanyuan Wu, Charles Ginther, Juri Kim, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2007
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCarolyn D Britten, Fairooz Kabbinavar, J Randolph Hecht, et al.
Cancer Research|December 20, 2007
RIN1 is a breast tumor suppressor geneMarc Milstein, Chelsea K Mooser, Hailiang Hu, et al.
Nature Reviews. Cancer|March 27, 2007
Shaping the future of biomarker research in breast cancer to ensure clinical relevanceM Carolina Hinestrosa, Kay Dickersin, Pamela Klein, et al.
Breast Cancer Research and Treatment|January 4, 2013
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancerStephen R D Johnston, Henry Gómez, Salomon M Stemmer, et al.
Breast Cancer Research : BCR|July 1, 2005
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapiesFrancisco J Esteva, Carol D Cheli, Herbert Fritsche, et al.
Pageof 5